Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end‐stage renal disease: Results from a randomized, phase 3 study-Reference-Cited by-同舟云学术

Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end‐stage renal disease: Results from a randomized, phase 3 study

Published:2019-09-19 Issue:2 Volume:11 Page:373-381
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J Diabetes Investig

Author:

Kaku Kohei¹^ORCID,Ishida Kazuyuki²,Shimizu Kohei²,Achira Meguru³,Umeda Yuusuke²

Affiliation:

1. Department of Medicine Kawasaki Medical School OkayamaJapan

2. Takeda Development Center Japan Takeda Pharmaceutical Company Limited OsakaJapan

3. Takeda PRA Development Center KK Osaka Japan

Funder

Takeda Pharmaceutical Company

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdi.13126

Reference22 articles.

1. International Diabetes Federation.IDF Diabetes Atlas 8th edition. 2017. Available from:http://www.diabetesatlas.orgAccessed October 2 2018.

2. Duration of diabetes and types of diabetes therapy in Japanese patients with type 2 diabetes: The Japan Diabetes Complication and its Prevention prospective study 3 (JDCP study 3)

3. Glycemic Variability: How Do We Measure It and Why Is It Important?

4. Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of the Utilization of Dipeptidyl Peptidase IV Inhibitors in Diabetic Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials;Diabetes, Metabolic Syndrome and Obesity;2024-03

2. Next-Generation Therapies for Type 2 Diabetes Mellitus;Smart Nanomaterials Technology;2024

3. Toward Revision of the ‘Best Practice for Diabetic Patients on Hemodialysis 2012’;Kidney and Dialysis;2022-10-04

4. Impact of Reduction in Pill Load Upon Use of a Once Weekly DPP-4 Inhibitor in 2 Cases of Type 2 Diabetes;Asploro Journal of Biomedical and Clinical Case Reports;2022-07-25

5. Safety and efficacy of once weekly dipeptidyl-peptidase-4 inhibitor trelagliptin in type-2 diabetes: A meta-analysis;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2022-04